Real-World Implementation of EndoConnect in Brazilian Primary Care: Formative Study of Usability, Engagement, and Equity in Digital Endometriosis Care

Background: Endometriosis is a chronic gynecological condition affecting approximately 10% of women of reproductive age worldwide and is associated with chronic pelvic pain, infertility, and reduced quality of life. In Brazil’s Unified Health System (Sistema Único de Saúde [SUS]), diagnostic delays frequently range from 7 to 10 years and disproportionately affect socially vulnerable populations, including rural, low-income, Black, and Indigenous women. Digital health interventions have been proposed as scalable solutions; however, most available applications are developed in high-income settings and do not align with the structural and operational realities of low- and middle-income countries (LMICs). Objective: This study aimed to evaluate feasibility, usability, acceptability, and user engagement associated with the real-world implementation of EndoConnect Alpha in primary health care settings, and to explore preliminary patterns of change in symptom burden, knowledge, and care navigation. Methods: A single-arm, prospective, formative implementation study was conducted in 10 primary health care units in Ceará, Brazil. A convenience sample of 60 participants, including women with suspected or confirmed endometriosis and primary care professionals, used the platform over an 8-week period under real-world conditions. Usability (assessed using the System Usability Scale), acceptability (assessed using the Technology Acceptance Model), engagement metrics, and exploratory outcomes were assessed. All analyses were exploratory, with no control group and no causal inference. Results: High usability and acceptability were observed, with strong user engagement, including a 79% completion rate of educational modules and consistent platform use. Observed decreases in pelvic pain and anxiety were identified, alongside increases in disease-related knowledge, self-reported therapy adherence, and reported gynecological referrals. A positive association between usability and acceptability was also observed. These findings should be interpreted as exploratory signals given the study design. Descriptive subgroup analyses suggested more pronounced trends among rural participants and those with a lower education level. Conclusions: The real-world implementation of EndoConnect Alpha demonstrated high feasibility, usability, and acceptability within a public primary care setting in a middle-income country. Observed trends suggest potential benefits, particularly among underserved populations; however, causal inference cannot be established. These findings support further controlled evaluation and highlight the relevance of equity-oriented digital health strategies tailored to LMIC contexts.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/a7ecf6193453258abef4e7e21acaeec7" />

<![CDATA[Study finds most bipolar depression outpatients have multiple comorbidities; many seek care, but substance use and phobias often go untreated.]]>

Opinion: MIT president: Why so many optimistic scientists are losing heart

Most successful scientists are optimists. They have to be, since the vast majority of experiments fail. In graduate school, I remember sitting in the lab at Rockefeller University in New York at 3 a.m., surrounded by stacks of culture dishes for growing cancer cells, none quite showing me what I hoped to find. But glimmers of interesting changes in the cells promised future success and made me feel the experiments wanted to work. That optimism drove me to keep trying. One day, they did work and I uncovered a new insight about a process in those cancer cells that no one had described before.

In 2026, there seem to be plenty of good reasons to be optimistic about science: Breakthroughs are everywhere.

Read the rest…

STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Today, we have some AI drug development news and an examination of the growing longevity industry.

The need-to-know this morning

  • The FDA has pushed back the decision date for AstraZeneca’s experimental breast cancer drug camizestrant, following a negative vote from a group of agency advisers, the company said. The extra time will allow the FDA to review additional analyses that AstraZeneca is providing. FDA advisers took issue with the study design of the pivotal SERENA-6 trial, though European regulators have recommended the drug be approved. AstraZeneca did not specify the new target date for an FDA decision.
  • Blackstone Life Sciences, a private equity fund, is providing Apogee Therapeutics with up to $1.3 billion to pay for the Phase 3 development and potential commercialization of zumilokibart, the biotech’s long-acting treatment for atopic dermatitis.

Kailera’s own ‘triple-G’ drug also looks very powerful

Kailera said yesterday that its investigational obesity drug that targets three hormones led to significant weight loss in a Phase 1 study. 

Continue to STAT+ to read the full story…

STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more

Good morning, everyone, and how are you today? The middle of the week has finally arrived, and you should congratulate yourselves for making it this far and deciding to soldier on. After all, consider the alternatives. None too pleasant, yes? This calls for a delicious cuppa stimulation. Our choice today is pomegranate green tea. As always, we invite you to join us. Meanwhile, here are some tidbits. Hope you have a meaningful and productive day, and please do keep in touch. We treasure your messages. …

The U.S. Food and Drug Administration ​has extended the decision deadline for an experimental breast cancer pill from AstraZeneca in order to review additional data, Reuters notes. The delay comes after a majority of an FDA ​advisory panel in April voted against the drug in ​combination with another type of therapy known ⁠as CDK4/6 inhibitor, due to concerns about the ​design of a key late-stage trial rather than ​its safety or efficacy. The company said it has submitted additional analyses requested by the FDA to support ​its new drug application, including data linked to ​longer-term efficacy outcomes that will be presented at a conference ‌on ⁠June 2. AstraZeneca’s camizestrant ​pill ⁠is designed for patients with a type of breast cancer in which tumors carry a specific mutation.

Brazil approved the country’s first generic version of Novo Nordisk’s Ozempic shot, opening the door to cheaper competition in one of the world’s fastest-growing markets for weight loss and diabetes drugs, Bloomberg News writes. EMS, a Brazilian pharmaceutical company, was cleared to sell its copycat drug, Ozivy, to treat adults with type 2 diabetes as an adjunct to diet and exercise. EMS plans to sell Ozivy for 30% less than Ozempic, and expects it to hit the market within 30 days. The approval marks a milestone for Brazil’s pharmaceutical industry as local drugmakers seek to enter the booming market for GLP-1 medicines, the class of drugs that includes Ozempic. The company plans to make 350,000 pens available initially and expects to sell about 1.2 million units in the first year.

Continue to STAT+ to read the full story…

STAT+: Where patients and hospitals disagree about AI

You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday. 

I really enjoyed Defector’s “Wow! America’s Graduating Seniors Really F—ing Hate AI!” piece (h/t to my colleague Jason Mast).

Sometimes I feel like a Negative Nathan here, but the degree to which college kids hate AI (even if they feel forced to use it) restores my belief that I am not wrong. There’s something special about being human, and we don’t have to surrender that just because powerful people (who didn’t have to deal with this as they tried to enter the workforce, or maintain a career) command us to.

Continue to STAT+ to read the full story…